Giuseppe Remuzzi

Summary

Affiliation: Istituto di Ricerche Farmacologiche Mario Negri
Country: Italy

Publications

  1. ncbi Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses
    Carlos Chiurchiu
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 16:S58-63. 2005
  2. ncbi The aggravating mechanisms of aldosterone on kidney fibrosis
    Giuseppe Remuzzi
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 19:1459-62. 2008
  3. ncbi The role of renin angiotensin system inhibition in kidney repair
    Irene M van der Meer
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Fibrogenesis Tissue Repair 3:7. 2010
  4. ncbi Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Clin Invest 116:288-96. 2006
  5. ncbi Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study
    Giuseppe Remuzzi
    Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Am Soc Nephrol 17:S90-7. 2006
  6. ncbi Overview of randomised trials of ACE inhibitors
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research and Unit of Nephrology and Dialysis, Ospedali Riuniti, Bergamo 24125, Italy
    Lancet 368:555-6. 2006
  7. ncbi Independent clinical research in Europe
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research, Bergamo and Milan, Italy
    Lancet 364:1723-6. 2004
  8. ncbi Rare diseases: what's next?
    Giuseppe Remuzzi
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Laboratori Negri Bergamo, 24125 Bergamo, Italy
    Lancet 371:1978-9. 2008
  9. ncbi Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation
    Giuseppe Remuzzi
    Department of Medicine and Transplantation, Ospedali Riuniti, Bergamo, Italy
    Am J Transplant 5:1146-50. 2005
  10. ncbi Investigational drugs for diabetic nephropathy
    Monica Cortinovis
    Mario Negri Institute for Pharmacological Research, Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Via Gavazzeni 11, 24125 Bergamo, Italy
    Expert Opin Investig Drugs 17:1487-500. 2008

Detail Information

Publications114 found, 100 shown here

  1. ncbi Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses
    Carlos Chiurchiu
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 16:S58-63. 2005
    ..The meta-analyses, however, represent a valuable tool to evaluate the consistency and generalizability of trial results to larger cohorts of patients...
  2. ncbi The aggravating mechanisms of aldosterone on kidney fibrosis
    Giuseppe Remuzzi
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 19:1459-62. 2008
    ..Nevertheless, further studies in larger populations with longer follow-up are warranted to address more definitely the safety and renoprotective effect of aldosterone antagonism in chronic kidney disease patients...
  3. ncbi The role of renin angiotensin system inhibition in kidney repair
    Irene M van der Meer
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Fibrogenesis Tissue Repair 3:7. 2010
    ..This is a desirable goal, considering the economic burden of chronic kidney diseases and their effect on morbidity and mortality...
  4. ncbi Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Clin Invest 116:288-96. 2006
    ..This review describes recent advances in our understanding of the mechanisms and mediators underlying renal tissue repair ultimately responsible for regression of renal injury...
  5. ncbi Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study
    Giuseppe Remuzzi
    Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Am Soc Nephrol 17:S90-7. 2006
    ..The apparent advantage of ACE inhibitors over other agents includes a protective effect on the kidney against the development of microalbuminuria, which is a major risk factor for cardiovascular events and death in this population...
  6. ncbi Overview of randomised trials of ACE inhibitors
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research and Unit of Nephrology and Dialysis, Ospedali Riuniti, Bergamo 24125, Italy
    Lancet 368:555-6. 2006
  7. ncbi Independent clinical research in Europe
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research, Bergamo and Milan, Italy
    Lancet 364:1723-6. 2004
  8. ncbi Rare diseases: what's next?
    Giuseppe Remuzzi
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Laboratori Negri Bergamo, 24125 Bergamo, Italy
    Lancet 371:1978-9. 2008
  9. ncbi Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation
    Giuseppe Remuzzi
    Department of Medicine and Transplantation, Ospedali Riuniti, Bergamo, Italy
    Am J Transplant 5:1146-50. 2005
    ..This case indicates that more fundamental research is needed before combined liver and kidney transplant is considered an option for children with HF-1-associated HUS...
  10. ncbi Investigational drugs for diabetic nephropathy
    Monica Cortinovis
    Mario Negri Institute for Pharmacological Research, Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Via Gavazzeni 11, 24125 Bergamo, Italy
    Expert Opin Investig Drugs 17:1487-500. 2008
    ..Diabetic nephropathy is one of the main causes of end-stage renal disease (ESRD) and is associated with elevated cardiovascular morbidity and mortality...
  11. ncbi Rituximab for idiopathic membranous nephropathy
    Giuseppe Remuzzi
    Ospedali Riuniti Di Bergam, Unit of Nephrology and Dialysis, Aldo and Cele Daccò Clinical Research Centre for Diseases, Mario Negri Institute for Parmacological Research, Via Gavazzeni 1124125, Bergamo, Italy
    Lancet 360:923-4. 2002
    ..CD20 B lymphocytes fell below normal ranges up to study end. The short-term risk-benefit profile of rituximab seems more favourable to that of any other immunosuppressive drug used to treat idiopathic membranous nephropathy...
  12. ncbi Routine renin-angiotensin system blockade in renal transplantation?
    Giuseppe Remuzzi
    Department of Immunology and Clinic of Organ Transplantation, Ospedali Riuniti di Bergamo and Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Curr Opin Nephrol Hypertens 11:1-10. 2002
    ....
  13. ncbi Which antihypertensive drugs are the most nephroprotective and why?
    Paolo Cravedi
    Mario Negri Institute of Pharmacological Research, Parco Scientifico Tecnologico Kilometro Rosso, Department of Medicine and Transplantation, Via Stezzano, 87, Ospedali Riuniti, 24126 Bergamo, Italy
    Expert Opin Pharmacother 11:2651-63. 2010
    ..Choice of antihypertensive strategies with highest nephroprotective effect is crucial to prevent or reverse progression to end stage renal disease (ESRD)...
  14. ncbi Combined kidney and liver transplantation for familial haemolytic uraemic syndrome
    Giuseppe Remuzzi
    Ospedali Riuniti, Bergamo, Italy
    Lancet 359:1671-2. 2002
    ..The operation was successful, and at discharge, the child had healthy kidney and liver function, with no sign of haemolysis...
  15. ncbi Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Ann Intern Med 136:604-15. 2002
    ..A multimodal approach that centers on reducing or removing all risk factors associated with the progression of renal disease may decrease the time to remission of the disease for most patients with proteinuric nephropathies...
  16. ncbi Why rare diseases?
    Giuseppe Remuzzi
    Laboratori Negri Bergamo, Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò, Ranica BG, Italy
    Ann Ist Super Sanita 47:94-7. 2011
    ..In other words, studying a rare condition may enlighten the path to other discoveries and to break the boundaries between disciplines and specialities to provide solutions for the sake of the patients...
  17. ncbi New therapeutics that antagonize endothelin: promises and frustrations
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Nat Rev Drug Discov 1:986-1001. 2002
    ..Here, we discuss preclinical and clinical results with endothelin antagonists, and consider possible approaches to fully realizing the potential of endothelin antagonism...
  18. ncbi Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Stem Cells 28:513-22. 2010
    ..Altogether these results highlight the potential of human CB-MSCs as future cell therapy for testing in human AKI...
  19. ncbi V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction
    Norberto Perico
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 76:960-7. 2009
    ..Our findings suggest that vasopressin receptor antagonists could be of additional therapeutic value in the treatment of chronic proteinuric nephropathy...
  20. ncbi Effect of seliciclib (CYC202, R-roscovitine) on lymphocyte alloreactivity and acute kidney allograft rejection in rat
    Anna Pezzotta
    Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Ranica, Bergamo, Italy
    Transplantation 85:1476-82. 2008
    ..T cell stimulation by alloantigens is followed by cell cycle progression, an event that is critically dependent on cyclin-dependent kinases...
  21. ncbi In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Am J Pathol 166:1309-20. 2005
    ..Increased ET-1 generation might alter glomerular permselectivity and amplify the noxious effect of protein overload on dysfunctional podocytes...
  22. ncbi Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin
    Cristina Zanchi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Immunol 181:1460-9. 2008
    ..coli O157:H7 infection...
  23. ncbi Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype
    Marina Noris
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Via Camozzi, 3 24020 Ranica Bg, Italy
    Clin J Am Soc Nephrol 5:1844-59. 2010
    ..Most childhood cases are caused by Shiga toxin-producing bacteria. The other form, atypical HUS (aHUS), accounts for 10% of cases and has a poor prognosis. Genetic complement abnormalities have been found in aHUS...
  24. ncbi Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes
    Elena Gagliardini
    Mario Negri Institute for Pharmacological Research, University of Bergamo, Bergamo, Italy
    Am J Physiol Renal Physiol 297:F1448-56. 2009
    ..These findings provide mechanistic insights to explain the antiproteinuric effect of this combined therapy in diabetes...
  25. ncbi Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Km Rosso, Via Stezzano, 87 24126 Bergamo, Italy
    Am J Physiol Renal Physiol 303:F1370-81. 2012
    ....
  26. ncbi Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Arthritis Rheum 56:1629-37. 2007
    ..To examine whether the cyclin-dependent kinase (CDK) inhibitor seliciclib ameliorates autoimmune nephritis in (NZB x NZW)F(1) mice...
  27. ncbi Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Km Rosso, Via Stezzano, 87, 24126 Bergamo, Italy
    Am J Physiol Renal Physiol 299:F1203-11. 2010
    ..These data suggest a strategy to target proteinuria to try to achieve regression of renal disease in diabetic patients who do not fully benefit from RAS inhibition alone...
  28. ncbi Dendritic cells genetically engineered with adenoviral vector encoding dnIKK2 induce the formation of potent CD4+ T-regulatory cells
    Susanna Tomasoni
    Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Transplantation 79:1056-61. 2005
    ....
  29. ncbi Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury
    Paola Cassis
    Transplant Research Center, Chiara Cucchi De Alessandri and Gilberto Crespi Mario Negri Institute for Pharmacological Research, Ranica, Bergamo, Italy
    Kidney Int 81:903-18. 2012
    ..Thus non-erythropoietic derivatives of EPO may be useful to prevent chronic renal allograft injury...
  30. ncbi Regulatory T cells and T cell depletion: role of immunosuppressive drugs
    Marina Noris
    Department of Immunology and Organ Transplantation, Ospedali Riuniti Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 18:1007-18. 2007
    ..These findings will be instrumental in developing "tolerance permissive" immunosuppressive regimens in the clinical setting...
  31. ncbi Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis
    Mauro Abbate
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Am J Pathol 161:2179-93. 2002
    ..Agents to reduce TGF-beta1, possibly combined with angiotensin blockade, should have priority in novel approaches to treatment of progressive nephropathies...
  32. ncbi Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Unit of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Via Gavazzeni 11, 24125 Bergamo, Italy
    Am J Pathol 169:1965-75. 2006
    ..These data suggest that the podocyte is a target of Stx, a novel stimulus for the synthesis of ET-1, which may control cytoskeleton remodeling and glomerular permeability in an autocrine fashion...
  33. ncbi Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury
    Piero Ruggenenti
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Bergamo, Italy
    Transplantation 84:956-64. 2007
    ..This might translate into more effective protection against chronic graft injury compared to cyclosporin A (CsA), which, in the same clinical setting, does not affect Treg...
  34. ncbi DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+CD25- cells with tolerogenic properties
    Sistiana Aiello
    Transplant Research Center, Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Transplantation 83:474-84. 2007
    ..Here we investigate the potency, the phenotype, and the mechanism of action of dnIKK2-DC-induced regulatory cells and we evaluated their tolerogenic properties in vivo...
  35. ncbi Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies
    Ruth Campbell
    Clinical Research Center for Rare Diseases Aldo and Cele Dacc, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 63:1094-103. 2003
    ..Long-term combined ACEi and ARA therapy may be more renoprotective than treatment with each agent alone...
  36. ncbi Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 66:1959-65. 2004
    ....
  37. ncbi Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, 11-24125 Bergamo, Italy
    J Am Soc Nephrol 17:1665-72. 2006
    ....
  38. ncbi Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Stem Cells 26:2075-82. 2008
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  39. ncbi The Toll-IL-1R member Tir8/SIGIRR negatively regulates adaptive immunity against kidney grafts
    Marina Noris
    Transplant Research Center Chiara Cucchi De Alessandri and Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Via Camozzi 3, 24020 Ranica, Bergamo, Italy
    J Immunol 183:4249-60. 2009
    ..Thus, TIR8 acts locally as a key regulator of allogeneic immune response in the kidney. Tir8 expression and/or signaling in donor tissue are envisaged as a novel target for control of innate immunity and amelioration of graft survival...
  40. ncbi Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells
    Simona Buelli
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 75:1050-9. 2009
    ..Thus, protein overload reduces the ability of the tubule cell to bind factor H and counteract complement activation, effects instrumental to renal disease progression...
  41. ncbi Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Nephron Exp Nephrol 104:e158-68. 2006
    ..We investigated whether in a two-kidney diabetic model the time at which treatment started predicted the response to TGFbeta antagonist...
  42. ncbi Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome
    Jessica Caprioli
    Mario Negri Institute for Pharmacologic Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Bergamo, Italy
    Blood 108:1267-79. 2006
    ..Hopefully this will translate into improved management and therapy of patients and will provide the way to design tailored treatments...
  43. ncbi Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings
    Eliana Gotti
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Italy
    J Am Soc Nephrol 14:755-66. 2003
    ..CsA reduction did not adversely affect histology. Per-protocol biopsy more than 1 yr after kidney transplantation is a safe procedure to guide change of drug regimen and to lower the risk of major side effects...
  44. ncbi Disruption of the Ang II type 1 receptor promotes longevity in mice
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, Bergamo, Italy
    J Clin Invest 119:524-30. 2009
    ....
  45. ncbi Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial
    Giuseppe Remuzzi
    Department of Renal Medicine, Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 18:1973-85. 2007
    ..In view of the cost, standard immunosuppression regimens for kidney transplantation should perhaps include azathioprine rather than MMF...
  46. ncbi Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Bergamo, Italy
    Kidney Int 65:2193-200. 2004
    ..Here we addressed the role of nephrin, CD2-associated protein (CD2AP), and podocin together with the integrity of the slit diaphragm in the pathogenesis of proteinuria of patients with diabetes and nephropathy...
  47. ncbi Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Clin J Am Soc Nephrol 5:1928-38. 2010
    ....
  48. ncbi Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition
    Daniela Macconi
    Mario Negri Institute for Pharmacological Research, Department of Biomedical Engineering, Laboratory of Renal Biophysics, Via Gavazzeni, 11, 24125 Bergamo, Italy
    Am J Pathol 174:797-807. 2009
    ..Increased parietal podocyte number in lisinopril-treated MWF rats suggests that the remodeling of Bowman's capsule epithelial cells contributes to this effect...
  49. ncbi Sirolimus therapy to halt the progression of ADPKD
    Norberto Perico
    Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 21:1031-40. 2010
    ..In summary, sirolimus halted cyst growth and increased parenchymal volume in patients with ADPKD. Whether these effects translate into improved long-term outcomes requires further investigation...
  50. ncbi Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Clin J Am Soc Nephrol 3:1652-9. 2008
    ..Whether this is associated with kidney function restoration and regression of the glomerular pathology was evaluated...
  51. ncbi Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement
    Marina Noris
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Dacc, Villa Camozzi-Ranica, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 16:1177-83. 2005
    ..In addition, a heterozygous mutation (causing an S890I change) in factor H of complement was found in the patient who developed chronic renal failure but not in her sister, who presented with exclusive neurologic symptoms...
  52. ncbi Propionyl-L-carnitine prevents early graft dysfunction in allogeneic rat kidney transplantation
    Nadia Azzollini
    Department of Immunology and Organ Transplantation, Ospedali Riuniti Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 74:1420-8. 2008
    ..The efficacy of propionyl-L-carnitine to modulate ischemia-reperfusion injury during transplantation suggests that its use in human transplantation is worth testing...
  53. ncbi The RAAS in the pathogenesis and treatment of diabetic nephropathy
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, 24125 Bergamo, Italy
    Nat Rev Nephrol 6:319-30. 2010
    ..Such findings will have major implications, particularly in settings where money and facilities are limited and in settings where renal replacement therapy is not available and the prevention of kidney failure is life saving...
  54. ncbi Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 14:1816-24. 2003
    ....
  55. ncbi How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 13:2898-908. 2002
    ..These data suggest a possible future strategy to induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients who do not fully respond to ACEi therapy...
  56. ncbi Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility
    Norberto Perico
    Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Department of Immunology and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Parco Scientifico Tecnologico Kilometro Rosso, via Stezzano 87, 24126 Bergamo, Italy
    Clin J Am Soc Nephrol 6:412-22. 2011
    ..Mesenchymal stromal cells (MSCs) abrogate alloimmune response in vitro, suggesting a novel cell-based approach in transplantation. Moving this concept toward clinical application in organ transplantation should be critically assessed...
  57. ncbi Preventing microalbuminuria in type 2 diabetes
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Villa Camozzi, Ranica, Bergamo, Italy
    N Engl J Med 351:1941-51. 2004
    ....
  58. ncbi Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Villa Camozzi, Ranica, Italy
    J Hypertens 29:207-16. 2011
    ..To address whether nondihydropyridine calcium-channel blocker added-on angiotensin-converting-enzyme inhibitor therapy ameliorates albuminuria and cardiovascular outcomes in type 2 diabetes patients...
  59. ncbi Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 17:3472-81. 2006
    ..As compared with trandolapril, Veratran may help with achievement of target BP with less need for concomitant antihypertensive medications...
  60. ncbi Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Lancet 365:939-46. 2005
    ....
  61. ncbi Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats
    Paola Cassis
    Transplant Research Center, Chiara Cucchi De Alessandri and Gilberto Crespi Mario Negri Institute for Pharmacological Research, Via Camozzi, Bergamo, Italy
    Transplantation 92:271-9. 2011
    ..Moreover, prolonged cold ischemia is a predictor of long-term graft loss in kidney transplant patients...
  62. ncbi Pretransplant donor peripheral blood mononuclear cells infusion induces transplantation tolerance by generating regulatory T cells
    Regiane Aparecida Cavinato
    Transplant Research Center, Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Transplantation 79:1034-9. 2005
    ..Regulatory activity is concentrated in the CD4+ CD25+ subset and requires cell-to-cell contact. Regulatory CD4+ T cells accumulate in tolerized kidney grafts where they could exert a protective function against host immune response...
  63. ncbi Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention
    Daniela Macconi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Am J Pathol 168:1073-85. 2006
    ..These data demonstrate that strategies aimed at stabilizing podocyte-podocyte contacts and targeting the relevant intracellular signal transduction are crucial to renoprotection...
  64. ncbi Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model
    Fabio Sangalli
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Physiol Renal Physiol 300:F1291-300. 2011
    ..They also suggest that evaluation of tubular protein concentration levels could help to identify patients at risk of kidney disease progression and to improve clinical management...
  65. ncbi Kidney failure stabilizes after an increase over 2 decades
    Paolo Cravedi
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Ren Care 33:100-4. 2007
    ..Early intervention may be important to maximize renoprotection, especially in diabetics...
  66. ncbi Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation
    Daniela Corna
    Mario Negri Institute for Pharmacological Research, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Am J Nephrol 27:630-8. 2007
    ..However, some safety concerns have been recently raised on the use of these agents, mainly due to transient episodes of proteinuria observed in patients receiving high doses of rosuvastatin...
  67. ncbi Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases, Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Diabetes Care 31:1629-34. 2008
    ..We sought to compare the effect of ACE versus non-ACE inhibitor therapy on incident electrocardiographic (ECG) evidence of LVH (ECG-LVH)...
  68. ncbi Chronic nephropathies: individual risk for progression to end-stage renal failure as predicted by an integrated probabilistic model
    Borislav D Dimitrov
    Clinical Research Center for Rare Diseases Aldo e Cele Dacc, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Nephron Clin Pract 95:c47-59. 2003
    ..This may help in optimizing care and costs in nephrology and other medical areas and designing trials in high-risk patients...
  69. ncbi Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Italy
    Clin J Am Soc Nephrol 3:1511-25. 2008
    ....
  70. ncbi Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors
    Dario Cattaneo
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Ren Nutr 15:71-6. 2005
    ..Preliminary studies have shown that a multidrug approach may induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients whose condition does not fully respond to a single treatment...
  71. ncbi Insulin-like growth factor-1 sustains stem cell mediated renal repair
    Barbara Imberti
    Mario Negri Institute for Pharmacological Research, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Am Soc Nephrol 18:2921-8. 2007
    ..These findings indicate that MSC exert beneficial effects on tubular cell repair in acute kidney injury by producing the mitogenic and pro-survival factor IGF-1...
  72. ncbi Does remission of renal disease associated with antihypertensive treatment exist?
    Paolo Cravedi
    Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, Bergamo, Italy
    Curr Hypertens Rep 9:160-5. 2007
    ..Early intervention, before progressive glomerulosclerosis and scarring is initiated by increased protein traffic, may be important to maximize reno- and cardioprotection, especially in diabetes...
  73. ncbi Timed urine collections are not needed to measure urine protein excretion in clinical practice
    Flavio Gaspari
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo-Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Kidney Dis 47:1-7. 2006
  74. ncbi Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade
    Aneliya Parvanova
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacc, Villa Camozzi, Mario Negri Institute for Pharmacological Research, 24125 Bergamo, Italy
    Expert Opin Pharmacother 6:1931-42. 2005
    ..Whether this also applies to diabetic nephropathy and related cardiovascular outcomes is still unknown...
  75. ncbi The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises
    Arrigo Schieppati
    Department of Medicine and Transplantation, Azienda Ospedaliera Ospedali Riuniti, Bergamo, Italy
    Kidney Int 64:1947-55. 2003
  76. ncbi Angiotensin receptors as determinants of life span
    Paola Cassis
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni, 11, 24125 Bergamo, Italy
    Pflugers Arch 459:325-32. 2010
    ....
  77. ncbi Proteinuria in diabetic nephropathy: treatment and evolution
    Ruth C Campbell
    Division of Nephrology and Dialysis, Ospedali Riuniti di Bergamo and Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11, Bergamo 24125, Italy
    Curr Diab Rep 3:497-504. 2003
    ..Screening and implementation of these strategies is needed to reverse the epidemic of diabetic renal disease...
  78. ncbi Clinical practice. Nephropathy in patients with type 2 diabetes
    Giuseppe Remuzzi
    Unit of Nephrology, Ospedali Riuniti di Bergamo, Italy
    N Engl J Med 346:1145-51. 2002
  79. ncbi Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinase-dependent pathways
    Roberta Donadelli
    Mario Negri Institute for Pharmacological Research and Unit of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Am Soc Nephrol 14:2436-46. 2003
    ..Fractalkine might contribute to direct mononuclear cells into peritubular interstitium and enhance their adhesion property, which in turn would favor inflammation and disease progression...
  80. ncbi Favorable effect of cotransfection with TGF-beta and CTLA4Ig of the donor kidney on allograft survival
    Susanna Tomasoni
    Mario Negri Institute for Pharmacological Research, Institute for Pharmacological Research, Bergamo, Italy
    Am J Nephrol 24:275-83. 2004
    ....
  81. ncbi Latest treatment strategies for membranous nephropathy
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Department of Renal Medicine, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Via Gavazzeni 11, 24125 Bergamo, Italy
    Expert Opin Pharmacother 8:3159-71. 2007
    ..This paper reviews the safety/efficacy profile of various agents that have been proposed as therapy for this disease, with particular focus on the latest, more specific and hypothesis-driven approaches...
  82. ncbi Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination
    Sanjib Kumar Sharma
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Italy
    Vasc Health Risk Manag 3:453-65. 2007
    ..Thus, trandolapril/verapamil is an effective option for treatment of hypertensive diabetes patients requiring more than one agent to achieve target blood pressure...
  83. ncbi Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation
    Dario Cattaneo
    Department of Immunology, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Kidney Int 62:1060-7. 2002
    ....
  84. ncbi The renin-angiotensin system in progression, remission and regression of chronic nephropathies
    Claudio Aros
    Mario Negri Institute for Pharmacological Research, Unit of Nephrology and Dialysis, Ospedali Riuniti di Bergamo, 24128-Bergamo, Italy
    J Hypertens Suppl 20:S45-53. 2002
    ..A multimodal approach aimed at reducing or abolishing all the risk factors for progression may shorten the time to remission for the majority of patients with proteinuric nephropathies...
  85. ncbi Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion
    Daniela Cugini
    Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Kidney Int 67:1753-61. 2005
    ..The possibility to modulate I/R injury in this rat model opens new perspectives for preventing posttransplant delayed graft function in humans...
  86. ncbi Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial
    Giuseppe Remuzzi
    Clinical Research Centre for Rare Diseases, Aldo e Cele Dacc, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Lancet 364:503-12. 2004
    ..Standard immunosuppression regimens for transplantation should perhaps include azathioprine rather than mycophenolate mofetil, at least for kidney grafts...
  87. ncbi Rituximab in idiopathic membranous nephropathy: a one-year prospective study
    Piero Ruggenenti
    , Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 14:1851-7. 2003
    ..The long-term risk/benefit profile of this novel, disease-specific approach seems much more favorable to that of commonly employed immunosuppressive drugs...
  88. ncbi Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease
    Jessica Caprioli
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Villa Camozzi, Via Camozzi 3, 24020 Ranica, Italy
    Hum Mol Genet 12:3385-95. 2003
    ..In conclusion HF1 mutations are frequent in patients with D-HUS (24%). Common polymorphisms of HF1 may contribute to D-HUS manifestation in subjects with and without HF1 mutations...
  89. ncbi Aldosterone and progression of kidney disease
    Monica Cortinovis
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Ther Adv Cardiovasc Dis 3:133-43. 2009
    ..Further studies in larger cohorts are now required to definitively address the safety and efficacy of aldosterone antagonism in patients with chronic kidney diseases...
  90. ncbi Hepatitis C infection and chronic renal diseases
    Norberto Perico
    Department of Medicine and Transplantation Ospedali Riuniti di Bergamo Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Clin J Am Soc Nephrol 4:207-20. 2009
    ....
  91. ncbi Intensified inhibition of renin-angiotensin system: a way to improve renal protection?
    Paolo Cravedi
    Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11 24125 Bergamo, Italy
    Curr Hypertens Rep 9:430-6. 2007
    ....
  92. ncbi Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Semin Nephrol 24:131-40. 2004
    ....
  93. ncbi The diabetic CKD patient--a major cardiovascular challenge
    Irene M van der Meer
    Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Ren Care 36:34-46. 2010
    ..Those involved in the delivery of care to patients with diabetes and CKD need to be aware of these issues and should adopt an individualised approach to treatment...
  94. ncbi Hyperhomocysteinemia and increased risk of retinopathy: a cross-sectional, case-control study in patients with type 2 diabetes
    Aneliya Parvanova
    Clinical Research Center for Rare Diseases Aldo e Cele Dacc, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Diabetes Care 25:2361. 2002
  95. ncbi Effect of high dose ramipril with or without indomethacin on glomerular selectivity
    Roberto Pisoni
    , Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Kidney Int 62:1010-9. 2002
    ..Combination with indomethacin is poorly tolerated and ineffective. Innovative approaches are needed to use ACEi more effectively...
  96. ncbi In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S. trial
    Norberto Perico
    Department of Medicine and Transplantation, Azienda Ospedaliera, Ospedali Riuniti di Bergamo-Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 65:1084-90. 2004
    ....
  97. ncbi Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results
    Giuseppe Remuzzi
    Clinical Research Center for Rare Diseases Aldo e Cele Dacc, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 15:3117-25. 2004
    ..Angiotensin II antagonism is a suitable and well-tolerated treatment for individuals with type 2 diabetes even with GFR levels approaching renal replacement therapy...
  98. ncbi Long-term outcome of renal transplantation from older donors
    Giuseppe Remuzzi
    Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy
    N Engl J Med 354:343-52. 2006
    ..This approach may help to expand the donor-organ pool for kidney transplantation...
  99. ncbi Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion
    Aneliya I Parvanova
    Aldo e Cele Dacco Clinical Research Centre for Rare Diseases, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, 24125 Bergamo, Italy
    Diabetes 55:1456-62. 2006
    ..Longitudinal studies are needed to clarify the role of insulin resistance in the pathogenesis of microalbuminuria and related complications...
  100. ncbi Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy
    Prue Hill
    Department of Anatomical Pathology, St Vincent's Hospital, 41 Victoria Parade, Fitzroy 3065, Victoria, Australia
    Nephrol Dial Transplant 20:1741-4. 2005
  101. ncbi Transplantation tolerance. A complex scenario awaiting clinical applicability
    Mohamed H Sayegh
    Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, Mass, USA
    Contrib Nephrol 146:95-104. 2005
    ..immunetolerance.org). In this review we will highlight the promise and challenges of making transplantation tolerance a clinical reality...